YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Immix Biopharma, Inc. – Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "we" or "us" or "IMMX"), a g…
LOS ANGELES, July 21, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Immix Biopharma, (“Immix" or the "Company") (NASDAQ: IMMX) investors that the firm has initiated an investigation into possible securities fraud, and may file a cl…
One of Rhode Island's most-wanted fugitives was captured Monday after apparently hiding out for 20 years as a biotech executive. Continue Reading
ATLANTA, July 20, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Immix Biopharma, Inc. (“Immix” or the “Company”) (NASDAQ: IMMX) complied with federal securities laws. On July 20, 2026, Immix disclosed that it had t…
BOSTON, July 20, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Immix Biopharma (Nasdaq: IMMX) for potential securities law violations. Investors who have lost money in their Immix Biopharma investment should contact the firm to…
Over the last 7 days, the United States market has dropped 2.7%, yet it remains up by 23% over the past year, with earnings forecasted to grow by 17% annually. In this dynamic environment, identifying high growth tech stocks involves looki…
[Financial market sector Healthcare on blue finance background from graphs, charts. 3D render] Vladimir Zakharov A screen of U.S. healthcare stocks with market capitalizations between $300M and $2B highlights several small-cap companies, i…
– Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, May 22, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in AL Amylo…
(RTTNews) - Immix Biopharma, Inc. (IMMX) announced that it has priced a $150 million underwritten registered offering of its common stock. Offering details The offering includes 16,778,524 shares of its common stock priced at $8.94 per sha…
(RTTNews) - Immix Biopharma, Inc. (IMMX) announced that it has achieved a complete response rate CR of 95% in the interim data of the NEXICART-2 trial evaluating NXC-201 in the treatment of relapsed/refractory AL Amyloidosis. Following the…
[Green arrow pointing up and a dollar sign] Immix Biopharma (IMMX [https://seekingalpha.com/symbol/IMMX]) traded higher after announcing data from a mid-stage trial for its lead asset, NXC-201, in AL amyloidosis, a rare disease characteriz…
– Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) – – CR rate now 95% (19 of 20 patients) – – All CRs reached within 1 year of follow-up post-dosing – – No relapses to-date observed for patient…
Over the last 7 days, the United States market has risen by 1.5%, contributing to a remarkable 26% climb over the past year, with earnings forecasted to grow by 17% annually. In this flourishing environment, growth companies with high insi…
Over the last 7 days, the United States market has risen by 2.2% and is up 31% over the past year, with earnings anticipated to grow by 17% annually in the coming years. In this favorable environment, identifying high growth tech stocks in…
Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) is one of the best fast growing penny stocks to buy right now. On May 7, Lexicon Pharmaceuticals reported Q1 2026 revenue of $21.1 million, a significant increase from $1.3 million in the prior y…
June S&P 500 E-Mini futures (ESM26) are trending up +0.46% this morning as investors shrugged off an exchange of fire between the U.S. and Iran and awaited the release of the key U.S. jobs report. The U.S. military said on Thursday that Ir…
Immix Biopharma Inc. (NASDAQ:IMMX) is one of the best performing NASDAQ stocks according to Wall Street analysts. On March 30, Immix Biopharma completed enrollment for its NEXICART-2 Phase 2 clinical trial, a key step toward seeking regula…
Immix Biopharma, Inc. – Full enrollment of BLA-enabling trial complete, per prior guidance – – Topline NEXICART-2 Results Expected Q3 2026, followed by BLA submission and planned commercial launch – – Onboarded Chief Medical Officer, forme…
– Full enrollment of BLA-enabling trial complete, per prior guidance – – Topline NEXICART-2 Results Expected Q3 2026, followed by BLA submission and planned commercial launch – – Onboarded Chief Medical Officer, formerly of Merck and Johns…
– Breakthrough Therapy Designation granted to NXC-201 based on positive NEXICART-2 Phase 2 interim clinical results, presented at the American Society of Hematology (ASH) 2025 annual meeting – – Final data expected this year followed by pl…
– Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in relapse…
(RTTNews) - Shares of Immix Biopharma Inc. (IMMX) are up nearly 20% at $6.65 in pre-market trade, following presentation of positive results of phase 2 portion of its NEXICART-2 trial in relapsed/refractory AL Amyloidosis at the American S…
Immix Biopharma (IMMX [https://seekingalpha.com/symbol/IMMX]) has priced an underwritten offering [https://seekingalpha.com/pr/20331107-immix-biopharma-announces-pricing-of-upsized-100-million-underwritten-offering-of-common] structured to…
LOS ANGELES, CA, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten registered offe…
– NXC-201 demonstrated a complete response (CR) rate of 75% (15/20) (at s/u IFE(-) level) by independent review committee – – In four out of five pending patients, MRD negativity in bone marrow predicts future complete response, potentiall…
* Immix Biopharma (IMMX [https://seekingalpha.com/symbol/IMMX])has appointed Michael Grabow as Chief Commercial Officer to drive all aspects of commercialization and launch for NXC-201 in relapsed/refractory AL Amyloidosis. * Prior to join…
- Former Chimerix (CMRX, acquired by Jazz for $935 million) Senior Commercial Leader Michael Grabow led Go-To-Market Strategy and Launch for rare disease therapeutic MODEYSO® - - Rare disease commercial veteran Mr. Grabow to lead Immix’s U…
- Oral presentation Sunday, December 7, at ASH 2025 - LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today anno…
LOS ANGELES, CA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present and host institutional…
Los Angeles, CA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present a NXC-201 abstract at t…
Los Angeles, CA, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, t…
– On track for first FDA Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL Amyloidosis – Los Angeles, CA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”,…
Immix Biopharma, Inc. – Dr. Chang led XOLAIR® from invention through FDA approval and commercialization, exceeding $5 billion in sales so far – Los Angeles, CA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Company”, “We” or “…
– Dr. Chang led XOLAIR® from invention through FDA approval and commercialization, exceeding $5 billion in sales so far – Los Angeles, CA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Company”, “We” or “Us”), a clinical-stage…
LOS ANGELES, CA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, tod…
Immix Biopharma, Inc. LOS ANGELES, CA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other…